Your browser is no longer supported. Please, upgrade your browser.
Settings
TEVA Teva Pharmaceutical Industries Limited daily Stock Chart
TEVA [NYSE]
Teva Pharmaceutical Industries Limited
Index- P/E- EPS (ttm)-6.03 Insider Own2.70% Shs Outstand1.05B Perf Week-6.59%
Market Cap18.05B Forward P/E4.28 EPS next Y4.01 Insider Trans0.00% Shs Float912.42M Perf Month0.82%
Income-6145.00M PEG- EPS next Q1.07 Inst Own60.30% Short Float5.01% Perf Quarter-47.26%
Sales23.37B P/S0.77 EPS this Y-96.10% Inst Trans1.85% Short Ratio2.25 Perf Half Y-47.60%
Book/sh23.97 P/B0.72 EPS next Y-7.29% ROA-6.70% Target Price24.73 Perf Year-66.03%
Cash/sh0.59 P/C29.30 EPS next 5Y-4.83% ROE-21.20% 52W Range15.22 - 51.51 Perf YTD-52.69%
Dividend1.10 P/FCF7.45 EPS past 5Y-53.00% ROI1.10% 52W High-66.63% Beta0.56
Dividend %6.41% Quick Ratio0.60 Sales past 5Y3.60% Gross Margin50.60% 52W Low12.94% ATR0.81
Employees56960 Current Ratio0.90 Sales Q/Q12.90% Oper. Margin-18.10% RSI (14)36.01 Volatility3.92% 4.19%
OptionableYes Debt/Eq1.44 EPS Q/Q- Profit Margin-26.30% Rel Volume0.44 Prev Close17.15
ShortableYes LT Debt/Eq1.39 EarningsAug 03 BMO Payout- Avg Volume20.38M Price17.19
Recom2.90 SMA202.63% SMA50-21.14% SMA200-43.03% Volume8,977,754 Change0.23%
Sep-21-17Reiterated Bernstein Mkt Perform $28 → $20
Sep-18-17Reiterated RBC Capital Mkts Underperform $21 → $15
Sep-11-17Upgrade BTIG Research Neutral → Buy
Aug-24-17Downgrade Credit Suisse Neutral → Underperform
Aug-16-17Downgrade Citigroup Buy → Neutral
Aug-07-17Downgrade Morgan Stanley Equal-Weight → Underweight
Aug-04-17Downgrade RBC Capital Mkts Outperform → Underperform $37 → $21
Aug-04-17Downgrade Credit Suisse Outperform → Neutral
Aug-04-17Downgrade Bernstein Outperform → Mkt Perform
Aug-03-17Downgrade Oppenheimer Outperform → Perform
Jul-17-17Reiterated RBC Capital Mkts Outperform $38 → $37
Jun-16-17Upgrade Mizuho Neutral → Buy $25 → $30
Jun-16-17Initiated Cantor Fitzgerald Neutral $31
Feb-28-17Downgrade Argus Buy → Hold
Feb-13-17Reiterated Maxim Group Hold $41 → $40
Feb-10-17Downgrade Mizuho Buy → Neutral $40 → $27
Jan-31-17Upgrade BofA/Merrill Neutral → Buy
Jan-31-17Reiterated Barclays Equal Weight $46 → $38
Jan-20-17Downgrade JP Morgan Overweight → Neutral
Jan-09-17Downgrade Wells Fargo Outperform → Market Perform
Sep-22-17 01:25PM  Generic Drug Makers Face Pricing Issues That Other Pharmas Don't Investor's Business Daily
Sep-21-17 04:18PM  Teva Pharmaceutical Industries Ltd. : TEVA-US: Dividend Analysis : August 29th, 2017 (record date) : By the numbers : September 21, 2017 Capital Cube
01:44PM  EQUITY ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
01:30PM  Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Teva Pharmaceutical Industries Ltd. Investors and Encourages Investors to Contact the Firm (TEVA) Business Wire
11:20AM  Scott+Scott, Attorneys at Law, LLP Reminds Investors of October 23rd Lead Plaintiff Deadline in Class Action Against Teva Pharmaceutical Industries Ltd. (TEVA) PR Newswire
07:37AM  [$$] Teva Pharmaceutical Stock Could Double Barrons.com
Sep-20-17 07:30PM  Our 5 Top Picks For A Booming Marijuana Market Oilprice.com
05:30PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Teva Pharmaceutical Industries Ltd. To Contact The Firm PR Newswire
05:14PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
11:56AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Teva Pharmaceutical Industries Ltd. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 23, 2017 TEVA GlobeNewswire
10:36AM  Teva/Nuvelution to Speed Up Development of Austedo in US Zacks
12:24AM  [$$] States Push Ahead With Investigation Into Opioid Painkillers The Wall Street Journal
Sep-19-17 06:05PM  [$$] States Push Ahead With Investigation Into Opioid Painkillers The Wall Street Journal
04:36PM  SHAREHOLDER ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
12:22PM  State attorneys general subpoena opioid makers and dealer... CNBC Videos
12:05PM  EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Teva Pharmaceutical Industries Ltd. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 23, 2017 - TEVA ACCESSWIRE
11:39AM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Teva Pharmaceutical Industries Limited to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit Business Wire
10:30AM  INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Teva Pharmaceutical Industries Ltd. Investors (TEVA) Business Wire
10:06AM  Teva shares rise on debt covenant amendments MarketWatch
10:00AM  Teva and Nuvelution Pharma Partner to Accelerate Development of AUSTEDO® (deutetrabenazine) Tablets for Use in Tourette Syndrome in the United States Business Wire
08:25AM  Teva shares rise 2% on debt covenant amendments MarketWatch
08:00AM  Today's Research Reports on Trending Tickers: Nutanix and Teva Pharmaceutical ACCESSWIRE
07:30AM  Teva Completes Amendment to Credit Facilities Business Wire
07:00AM  A New CEO Only Emboldens the Case for Teva Pharmaceutical Industries Ltd (TEVA) Stock InvestorPlace
12:51AM  [$$] Teva Sells Slate of Womens Health Products in Debt-Reducing Moves The Wall Street Journal
Sep-18-17 04:30PM  Why Teva Pharmaceutical Industries, Pier 1 Imports, and Kinross Gold Slumped Today Motley Fool -6.13%
04:07PM  S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed TheStreet.com
02:37PM  S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed TheStreet.com
01:50PM  $1.38 billion payday: Teva signs 2 deals for remaining women's health assets American City Business Journals
01:04PM  Teva: When Bold Action Just Isn't Possible Barrons.com
12:37PM  Why Allergan Could Be A $300 Stock Barrons.com
12:29PM  [$$] CVC Buys $703 Million Women's Drug Portfolio from Teva The Wall Street Journal
11:32AM  TEVA SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Teva Pharmaceutical Industries Ltd. and a Lead Plaintiff Deadline of October 23, 2017 ACCESSWIRE
11:30AM  New Initiative Creates Scalable Solutions to Improve Care of Patients with Multiple Chronic Conditions Business Wire
10:38AM  [$$] Teva Sells Slate of Women's Health Products The Wall Street Journal
10:33AM  Valeant Pharmaceuticals: Is A New Drug Approval On The Horizon? Barrons.com
10:17AM  Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed TheStreet.com
08:57AM  Teva Pharma to sell more women's health assets for $1.38 bln Reuters
08:23AM  Teva Pharma to sell some women's health assets for $1.38 bln Reuters
08:18AM  Teva sells its remaining women's health assets for $1.4 billion MarketWatch
08:07AM  Teva Announces Sale of Remaining Assets in Specialty Global Womens Health Portfolio for $1.38 Billion Business Wire
Sep-16-17 10:47AM  Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher? Motley Fool
07:00AM  Teva's New CEO Brings This Secret Weapon TheStreet.com
Sep-15-17 11:24PM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
10:50PM  TEVA PHARMACEUTICAL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Teva Pharmaceutical Industries Limited (TEVA) PR Newswire
11:24AM  INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Teva Pharmaceutical Industries Ltd. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 23, 2017 - TEVA ACCESSWIRE
10:37AM  Behind TEVAs Womens Health Products after 1H17 Market Realist
09:07AM  Why New Generic Products Could Boost TEVAs Revenue Growth Market Realist
07:36AM  The Latest on TEVAs Oncology Business Market Realist
06:52AM  Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO Zacks
Sep-14-17 01:55PM  Company under fire for opioid marketing files patent suit Associated Press
01:19PM  INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
12:13PM  Is It Too Late To Buy Teva Pharmaceutical Industries Limited (TEVA)? Simply Wall St.
12:08PM  Go Long Teva Pharmaceuticals Industries Ltd (ADR) (TEVA) Stock With Less Speculation InvestorPlace
11:57AM  The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Teva Pharmaceutical Industries Ltd. Shareholders and a Lead Plaintiff Deadline of October 23, 2017 Business Wire
10:37AM  How TEVAs Respiratory Franchise Is Positioned after 1H17 Market Realist
09:07AM  How TEVAs CNS Drugs Performed in 1H17 Market Realist
08:00AM  Teva to Present Data for AUSTEDO® (deutetrabenazine) Tablets and Other Research at the 2017 Psych Congress Business Wire
07:39AM  TEVA Depends on This for Revenue Growth Market Realist
Sep-13-17 04:42PM  IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Encourages Investors with Losses to Contact the Firm GlobeNewswire
04:32PM  Teva to sell women's health assets to CVC Capital Partners - Report Reuters
02:07PM  CVC Nears Deal for Tevas European Women's Health Assets Bloomberg
12:44PM  TEVA INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Teva Pharmaceutical Industries Ltd. and a Lead Plaintiff Deadline of October 23, 2017 Business Wire
10:51AM  Teva's Leukemia Drug sNDA Granted Priority Review by the FDA Zacks
10:39AM  Company News For Sep 13, 2017 Zacks
10:37AM  How TEVAs Generic Medicines Franchise Is Positioned after 1H17 Market Realist
09:14AM  A Look At Teva's Paragard IUD Asset Sale To Cooper Companies, From Both Sides Benzinga
09:08AM  Inside Teva Pharmaceuticals 1H17 Performance Market Realist
08:40AM  Major Pharma Short Interest Surges 24/7 Wall St.
07:41AM  Teva Pharmaceutical on the Street: Analysts Recommendations in September Market Realist
07:23AM  3 PR Scandals Creating Intriguing Buying Opportunities Motley Fool
Sep-12-17 06:15PM  IMPORTANT EQUITY ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Encourages Investors with Losses to Contact the Firm GlobeNewswire
05:44PM  INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Teva Pharmaceutical Industries Ltd. Investors (TEVA) Business Wire
03:33PM  Teva's New CEO Brings No Relief: Generic Drugmakers to Dump Zacks
01:11PM  Teva Pharma showing strong gains, IQ100 up 22% CNBC Videos
12:34PM  EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Teva Pharmaceutical Industries Ltd. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 23, 2017 Business Wire
12:30PM  $1.1B deal: Teva sells Paragard in 'important step' for stakeholders American City Business Journals
10:17AM  Company News For Sep 12, 2017 Zacks
10:17AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Teva Pharmaceutical Industries Ltd. (TEVA) & Lead Plaintiff Deadline October 23, 2017 ACCESSWIRE
10:11AM  With New CEO In Place, Focus For Teva Pharma Turns To 'Execution' Benzinga
10:04AM  Tuesdays Vital Data: Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Snap Inc (SNAP) and Tesla Inc (TSLA) InvestorPlace
09:56AM  Teva Pharmaceutical Has a Long Road Back TheStreet.com
09:39AM  Stocks Open Higher; S&P 500 Aces New Record, DowDuPont Breaks Out Investor's Business Daily
09:14AM  Valeant Pharmaceuticals Intl Inc (VRX) Stock Is STILL Too Ugly to Buy InvestorPlace
08:10AM  Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and Teva Pharmaceutical Industries ACCESSWIRE
08:02AM  Cooper Companies Buys Teva's PARAGARD Intrauterine Platform Zacks
08:00AM  Teva Receives FDA Priority Review for First Line Use of TRISENOX® (arsenic trioxide) in Patients with Low to Intermediate Risk Acute Promyelocytic Leukemia (APL) Business Wire
07:20AM  Featured Company News - Teva Pharmaceuticals Presents Outcome Measure Results from Phase-III Clinical Trials for the Potential of Fremanezumab to Treat Migraine Patients ACCESSWIRE
05:43AM  Teva Surges Once Again on $1.1 Billion Sale and New CEO TheStreet.com
12:41AM  [$$] Now Comes the Hard Part at Teva The Wall Street Journal
12:41AM  Teva Appoints New Chief Executive After Months of Speculation The Wall Street Journal
12:03AM  [$$] New Teva chief must tackle 'tough decisions' on jobs Financial Times
Sep-11-17 09:55PM  Teva to Sell ParaGard for $1.1 Billion to Reduce Debt Bloomberg +19.35%
07:27PM  PRESS DIGEST- Financial Times - Sept 12 Reuters
06:19PM  Teva to sell contraceptive brand Paragard in $1.1 bln deal Reuters
05:34PM  UPDATE 1-Teva to sell contraceptive brand Paragard in $1.1 bln deal Reuters
04:49PM  Teva Rockets After Hiring Former Novo Nordisk Exec As CEO Investor's Business Daily
04:48PM  [$$] Now Comes the Hard Part at Teva The Wall Street Journal
04:33PM  Teva to sell its contraceptive brand Paragard in $1.1 bln deal Reuters
04:31PM  Cooper Cos. buys Teva IUD line for $1.1 billion MarketWatch
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women's health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson's disease; and Nuvigil for the treatment of excessive sleepiness associated with narcolepsy and certain other disorders. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda/Bendeka, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. This segment also offers a portfolio of products in the women's health category, which includes ParaGard, Plan B One-Step, and OTC/Rx, as well as other products. The company has collaboration arrangements with Attenukine, Procter & Gamble Company, and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.